Deals & IPOs

Viatris Closes $36.50-Per-Share Pacira Acquisition

Viatris closed its $36.50-per-share cash acquisition of Pacira BioSciences after a tender offer drew 66.46% of shares, creating a wholly owned subsidiary in non-opioid pain management.

By Amara Osei

3 min read

Viatris Completes Acquisition Of Pacira BioSciences For $36.50 Per Share
Viatris Completes Acquisition Of Pacira BioSciences For $36.50 Per Sharejarmoluk / pixabay

What's News

  • Viatris completed its acquisition of Pacira BioSciences at $36.50 per share in cash, announced October 8, 2026.
  • About 32.9 million shares — 66.46% of Pacira stock — were tendered before the offer expired just after 11:59 p.m. ET on November 16.
  • The merger closed under Section 251(h) of Delaware law, with no separate shareholder vote; Pacira shares will be delisted from Nasdaq.
  • Viatris forecasts $90–100 million in revenue from the deal between November 17 and December 31, 2026.
  • CEO Scott A. Smith said the deal aims to 'establish a leadership position in non-opioid pain management.'

Viatris completed its acquisition of Pacira BioSciences at $36.50 per share in cash, closing a deal announced October 8, 2026 through a cash tender offer followed by a merger. Pacira is now a wholly owned Viatris subsidiary, and its shares will be delisted from the Nasdaq Global Select Market.

The tender offer expired one minute after 11:59 p.m. Eastern Time on November 16. Approximately 32.9 million shares were validly tendered and not withdrawn — about 66.46% of Pacira's outstanding stock, according to Viatris. After the tender conditions were satisfied or waived, Peach Purchaser Sub, a wholly owned Viatris subsidiary, accepted the shares for payment.

The price is $36.50 in cash per outstanding share, before applicable withholding taxes and without interest.

How did the deal close without a shareholder vote?

Peach Purchaser Sub merged into Pacira under Section 251(h) of Delaware's corporate law. That provision lets qualifying acquisitions proceed without a separate shareholder vote once a tender offer meets the required conditions. Pacira survived the merger and became a wholly owned Viatris unit.

Shareholders who didn't tender didn't escape the deal. Their shares converted into the right to receive the same $36.50-per-share cash consideration.

What does Pacira bring to Viatris?

The acquisition adds Pacira's non-opioid pain-management products and expertise to Viatris' portfolio. Viatris said the two businesses have complementary products and capabilities that can support a leadership position in the market.

Non-opioid pain management has drawn greater attention as healthcare providers look for approaches that control pain while reducing reliance on opioids. Actual treatment decisions, the company noted, depend on the patient, procedure, clinical evidence, approved labeling, and physician judgment.

The deal also transfers people, not just products. Viatris gains employees with specialized experience in developing and marketing non-opioid treatments, plus additional commercial, medical and operational capabilities in pain management.

CEO Scott A. Smith framed the closing as strategic follow-through. "Today marks an important milestone in the execution of our strategy to strengthen our U.S. innovative medicines business," Smith said. "With Pacira now part of Viatris, we are bringing together complementary portfolios, capabilities and expertise to establish a leadership position in non-opioid pain management."

He added: "We are excited to welcome our new Pacira colleagues as we create new opportunities to make a meaningful difference for patients and accelerate our path to sustained revenue and earnings growth."

How much revenue will the deal add this year?

Viatris expects the acquisition to contribute between $90 million and $100 million in revenue from November 17 through December 31, 2026. That's a company forecast, subject to operating performance and other factors during the post-acquisition period.

The transaction forms part of Viatris' strategy to strengthen its U.S. innovative medicines business. The company keeps a broader portfolio spanning generics, established brands, value-added medicines, and innovative therapies. Viatris is headquartered in the United States, with global centers in Pittsburgh, Shanghai, and Hyderabad, India.

The closing completes the ownership transfer, but the harder work starts now. Viatris still has to integrate Pacira's personnel, products, operations, and systems — and how smoothly that goes will shape the acquisition's longer-term financial and strategic impact.

Source: pulse2.com

Share this article:

More from Amara Osei

Amara Osei

Show full bio

Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.

2,260 articles

Related articles

« Previous article